Drugs / CI-135
CI-135
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05266950 | Dec 2021 → Dec 2023 | acute myeloid leukemia | Beijing Boren Hospital | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CI-135 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05266950 ↗ |
| Known as | CI-135 CAR-T | “CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)” NCT05266950 ↗ |
| Known as | CI-135 CAR-T cells | “CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)” NCT05266950 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cell treatment” NCT05266950 ↗ |
| Route | Intravenous | “infused intravenously” NCT05266950 ↗ |